Incidence of inhibitor development in PUPs with severe Haemophilia A in the CEE region between 2005 and 2015
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F21%3A00073328" target="_blank" >RIV/65269705:_____/21:00073328 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/21:00121759
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0049384820306514" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0049384820306514</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.thromres.2020.12.004" target="_blank" >10.1016/j.thromres.2020.12.004</a>
Alternative languages
Result language
angličtina
Original language name
Incidence of inhibitor development in PUPs with severe Haemophilia A in the CEE region between 2005 and 2015
Original language description
Introduction: This study analyses real-world data on 144 previously untreated patients (PUPs) with severe Haemophilia A, from seven countries in Central and Eastern Europe (CEE: Bulgaria, Croatia, Czech Republic, Hungary, Latvia, Serbia, and Slovenia), over a period of 11 years. It analyses the risk factors associated with development of inhibitors to factor VIII concentrates. Methods: Cox proportional hazard models were used to estimate the hazard risk of factors possibly influencing the development of inhibitors. Patients were followed for up to 100 exposure days (EDs). Results: Cumulative inhibitor incidence at the time of 100 EDs was 18.7%, slightly lower than the 25-35% incidence reported in most studies. Of PUPs who developed inhibitors, a majority (56%) developed them within the first 20 EDs and 88% by the 50th ED. FVIII class (recombinant or plasma-derived) did not influence the inhibitors' incidence rate (p = 0.64). We found a significant protective effect of prophylaxis compared to on-demand treatment (p = 0.003). PUPs who had an intensive peak treatment during the first 50 EDs were at significantly higher risk for inhibitor development (HR (95% CI) 5.3 (2.3-12.5), p < 0.001). Conclusion: Inhibitors are and will continue to be the most significant complication of haemophilia treatment with factor concentrates. This is particularly true for haemophilia A. In our cohort, we were able to show that the treatment regimen used during first 50EDs influenced significantly the inhibitor risk, but the class of the factor concentrate did not play an important role. Real world data will remain one of the important resources for improving our knowledge of haemophilia.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Thrombosis Research
ISSN
0049-3848
e-ISSN
—
Volume of the periodical
198
Issue of the periodical within the volume
FEB
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
196-203
UT code for WoS article
000616053200031
EID of the result in the Scopus database
2-s2.0-85098139704